Ich würde dieser Studie Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia J Am Acad Dermatol 2000 Nov;43(5 Pt 1):768-76.
nicht unbedingt blind vertrauen.Die Frage ist 1. hatten die Probandinnen überhaupt alle AGA?2.Wie weit war deren Aga fortgeschritten,war da überhaupt noch etwas zu machen?3Es ist nicht so das eine Dehydrotestosteron-Absenkung die ultimative Wunderwaffe ist,meisstens reicht das in Einzelanwendung nicht aus,da noch andere Faktoren eine Rolle bei den hormonellen Haarausfall spielen.4.Es könnte sein,das 1 mg bei dieser Personengruppe zu wenig war.In der Regel unterbindet man eine Dehydrotestosteron-Synthese bei Frauen mit 2,5-5 mg Finasterid(Studie anbei)

Ob es bei postmenopausalen Frauen trotz dieser Studie wirkt,kann ich nicht belegen,aber das es bei Frauen generell wirkt geht aus dieser Studie hervor,hier zwar an Patientinnen mit Hirsutismus,aber es geht in beiden Fällen um ein Unterbinden der DHT-Synthese.

A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.

Kelestimur F, Everest H, Unluhizarci K, Bayram F, Sahin Y

Eur J Endocrinol 2004 Mar;150(3):351-4.
Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey. FAU - Kelestimur, Fahrettin
PMID: 15012621 [PubMed - indexed for MEDLINE]

OBJECTIVE: To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism. PATIENTS AND MEASUREMENTS: Sixty-five hirsute women were randomly assigned to one of these two treatment groups. Hirsutism score was measured according to the modified Ferriman-Gallwey scoring system. Baseline and post-treatment assessments were carried out in each subject by an investigator blinded to the therapy. Both groups had similar demographic properties at baseline. The serum levels of total and free testosterone, dehydroepiandrosterone sulphate and sex hormone-binding globulin were measured at the beginning and after 1 year of therapy. Blood chemistry and side-effects were evaluated during the study. Hirsutism scores were decreased significantly in both groups at the end of the year. RESULTS: The mean percentage change in hirsutism scores from baseline in the spironolactone plus finasteride-treated group (51.3%) was significantly (P<0.005) higher than in the group treated with spironolactone alone (36.6%). Patients from both treatment groups experienced similar side-effects. CONCLUSIONS: We have concluded that a combination of spironolactone plus finasteride is a safe and effective therapy in the treatment of hirsutism.

Hier wird zwar auch gesagt,das es bei Postmenopausalen Frauen nicht wirkt,jedoch wurde bei jüngeren Frauen eine Stabilisierung der AGA beobachtet.

Hair loss in women with hyperandrogenism: four cases responding to finasteride.

Shum KW, Cullen DR, Messenger AG

J Am Acad Dermatol 2002 Nov;47(5):733-9.
Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK. FAU - Shum, Kid Wan
PMID: 12399766 [PubMed - indexed for MEDLINE]

Oral finasteride, a type II 5 alpha-reductase inhibitor, has been shown to increase hair growth and slow progression of thinning in men with androgenetic or male pattern balding (Hamiliton type) but has no affect on hair growth in postmenopausal women with female pattern hair loss (Ludwig type). We describe 4 cases of hair loss with characteristics of both male and female patterns in women with hyperandrogenism in which finasteride has improved or stabilized the alopecia. Improved hair growth was seen after 6 months, 1 year, 2 years, and 2.5 years, respectively. The finding that finasteride treatment improves pattern hair loss in women with hyperandrogenism but does not affect those postmenopausal women with female pattern hair loss without hyperandrogenism supports the concept that not all types of female hair loss have the same pathophysiology.